Jinlong Song

Jinan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Jiawei Qi Gong Wan Improves Endometrial Receptivity in PCOS-like Mice by Attenuating Inflammation: A Multi-Omics Study Linking Gut Microbiota and Metabolite Profiles.

Jiawei Qi Gong Wan Improves Endometrial Receptivity in PCOS-like Mice by Attenuating Inflammation: A Multi-Omics Study Linking Gut Microbiota and Metabolite Profiles.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: April 06, 2026

Development and Validation of the TCAP Nomogram for Predicting Hepatotoxicity Risk in Hepatocellular Carcinoma Patients Receiving TACE Combined with Systemic Therapy.

Development and Validation of the TCAP Nomogram for Predicting Hepatotoxicity Risk in Hepatocellular Carcinoma Patients Receiving TACE Combined with Systemic Therapy.

Journal: Journal of hepatocellular carcinoma

Published: February 14, 2026

Correction: Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas.

Correction: Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas.

Journal: Frontiers in immunology

Published: August 06, 2025

Bioinformatics-Based Identification of Platelet-Related Genes and Analysis of Immune Infiltration Landscape in Endometriosis.

Bioinformatics-Based Identification of Platelet-Related Genes and Analysis of Immune Infiltration Landscape in Endometriosis.

Journal: Clinical laboratory

Published: July 15, 2025

Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas.

Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas.

Journal: Frontiers in immunology

Published: June 08, 2025

Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.

Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.

Journal: Hepatology (Baltimore, Md.)

Published: October 27, 2024

Risk Factors and Predictive Analysis of Acute Severe Abdominal Pain After Hepatic Artery Infusion Chemotherapy in Patients with Hepatocellular Carcinoma.

Risk Factors and Predictive Analysis of Acute Severe Abdominal Pain After Hepatic Artery Infusion Chemotherapy in Patients with Hepatocellular Carcinoma.

Journal: Journal of hepatocellular carcinoma

Published: September 04, 2024

Jiawei Qi Gong Wan improves liver fibrosis and inflammation in PCOS mice via the Akt2-FoxO1 and YAP/TAZ signaling pathways.

Jiawei Qi Gong Wan improves liver fibrosis and inflammation in PCOS mice via the Akt2-FoxO1 and YAP/TAZ signaling pathways.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: May 12, 2024

Efficacy and Safety Analysis of Transarterial Chemoembolization Plus Donafenib With or Without Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Prospective, Single-Arm, Single-Center, Phase II Clinical Study.

Efficacy and Safety Analysis of Transarterial Chemoembolization Plus Donafenib With or Without Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Prospective, Single-Arm, Single-Center, Phase II Clinical Study.

Journal: Journal of hepatocellular carcinoma

Published: May 07, 2024

Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆.

Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆.

Journal: JHEP reports : innovation in hepatology

Published: December 15, 2023

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.

Journal: Frontiers in immunology

Published: March 17, 2023

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma.

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma.

Journal: Therapeutics and clinical risk management

Published: December 09, 2022

Showing 1-12 of 32

Last Updated: 09/26/2026